XML 58 R39.htm IDEA: XBRL DOCUMENT
v3.20.1

Collaborative Arrangements - Narrative (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | 21 Months Ended | 29 Months Ended | 37 Months Ended
--- | --- | --- | --- | --- | --- | ---
Mar. 31, 2021 | Mar. 31, 2020 | Jan. 31, 2020 | Mar. 31, 2019 | Mar. 31, 2018 | Jul. 31, 2017 | Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2019 | Dec. 31, 2019 | Mar. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  | $ 2,209 | $ 1,931 |  |  |  |  |
Other liabilities, noncurrent |  | $ 11,550 |  |  |  |  | 11,550 |  | $ 11,970 |  | $ 11,970 | $ 11,970 |
Lynparza | Other Assets |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets |  | 928 |  |  |  |  | 928 |  |  |  |  |  |
Lenvima | Other Assets |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets |  | 921 |  |  |  |  | 921 |  |  |  |  |  |
Adempas | Other intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets |  | 844 |  |  |  |  | 844 |  |  |  |  |  |
AstraZeneca |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and milestone payments |  |  |  |  |  | $ 1,600 |  |  |  |  |  |  |
License option payment related to collaborative arrangement |  |  |  |  |  | $ 750 |  |  |  |  |  |  |
AstraZeneca | Sales-Based Milestones |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent milestone payments collaborative arrangement |  |  |  |  |  |  | 3,100 |  |  |  |  |  |
AstraZeneca | Sales-Based Milestones | Lynparza |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Probable contingent payments collaborative arrangement |  |  |  |  |  |  |  |  |  |  |  | $ 1,000 |
Milestone payments made to collaborative partner |  |  | $ 250 |  |  |  |  |  | 200 | $ 250 |  |  |
AstraZeneca | Regulatory Milestones | Lynparza |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments made to collaborative partner |  |  |  |  |  |  |  |  | 60 | 140 |  |  |
Contingent milestone payments collaborative arrangement |  |  |  |  |  |  | 1,700 |  |  |  |  |  |
Eisai |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and milestone payments |  |  |  |  | $ 750 |  |  |  |  |  |  |  |
License option payment related to collaborative arrangement |  | $ 200 |  | $ 325 |  |  |  |  |  |  |  |  |
Eisai | Forecast |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
License option payment related to collaborative arrangement | $ 125 |  |  |  |  |  |  |  |  |  |  |  | $ 650
Eisai | Sales-Based Milestones |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent milestone payments collaborative arrangement |  |  |  |  |  |  | 3,000 |  |  |  |  |  |
Eisai | Sales-Based Milestones | Lenvima |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Probable contingent payments collaborative arrangement |  |  |  |  |  |  |  |  |  |  | $ 950 |  |
Milestone payments made to collaborative partner |  |  |  |  |  |  | 300 |  | $ 50 |  |  |  |
Eisai | Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent milestone payments collaborative arrangement |  |  |  |  |  |  | 135 |  |  |  |  |  |
Eisai | Regulatory Milestones | Lenvima |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments made to collaborative partner |  |  |  |  |  |  |  |  |  | 250 |  |  |
Bayer AG | Sales-Based Milestones |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Probable contingent payments collaborative arrangement |  |  |  |  |  |  |  |  |  | 725 |  |  |
Milestone payments made to collaborative partner |  |  |  |  |  |  |  |  |  | $ 350 |  |  |
Contingent milestone payments collaborative arrangement |  |  |  |  |  |  | $ 400 |  |  |  |  |  |

X
- Definition Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement. + References No definition available. + Details
Name: | mrk_ContingentPaymentsCollaborativeArrangement
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License option payment related to collaborative arrangement + References No definition available. + Details
Name: | mrk_Licenseoptionpaymentrelatedtocollaborativearrangement
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone Payments Made to Collaborative Partner + References No definition available. + Details
Name: | mrk_MilestonePaymentsMadetoCollaborativePartner
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Probable Contingent Payments Collaborative Arrangement + References No definition available. + Details
Name: | mrk_ProbableContingentPaymentsCollaborativeArrangement
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront and milestone payments made to partner as part of collaborative arrangement. + References No definition available. + Details
Name: | mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_OtherLiabilitiesNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrk_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mrk_SalesBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mrk_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrk_EisaiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrk_BayerAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |